Niagen Bioscience Inc. (NASDAQ:NAGE) is one of the 10 best consumer staples penny stocks to buy now.
On April 9, Niagen Bioscience Inc. (NASDAQ:NAGE) announced that Nicotinamide Riboside Chloride, the patented form of nicotinamide riboside used in its key product, Niagen, was granted an official dietary supplement ingredient monograph by the United States Pharmacopeia.
Copyright: zneb076 / 123RF Stock Photo
Following the announcement, the CEO, Rob Fried, pointed out that it was an important milestone for the entire NAD+ supplement sector. As he explained, NR had become the only substance within this group to be provided with a published standard by the Pharmacopeia, while NMN and NAD+ lacked such standards. Such developments around Niagen have led to a favorable sentiment for the stock, which is one of the most promising consumer staples names.
Back on March 10, the company shared that it had obtained US Patent No. 12,558,367 Niagen. This intellectual property expansion was backed by the company’s vigorous efforts to create a vast competitive moat around commercial longevity science. As the natural cellular energy levels gradually decrease with aging, the wellness sector as a whole is quickly shifting from simple oral supplements to extremely effective therapeutic delivery systems.
Rob Fried, the CEO, stated unequivocally that this particular patent ensures crucial intellectual protection through 2044. This demonstrates the company’s uniqueness in providing a much better aqueous-based solution under the new Niagen Plus brand. In fact, it fully avoids the physical discomfort typically associated with these particular IV medicines while circumventing normal digestion to enable far faster infusion times.
Niagen Bioscience Inc. (NASDAQ:NAGE) is involved in the development and commercialization of aging products. It sells the dietary supplement nicotinamide adenine dinucleotide (NAD+), pharmaceutical- and food-grade Niagen, and the NAD+ precursor nicotinamide riboside. It sells products through multiple channels like e-commerce, specialty retailers, and licensed healthcare resellers.
While we acknowledge the risk and potential of NAGE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NAGE and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.